

Flemming Bendtsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6424196/publications.pdf>

Version: 2024-02-01

108
papers

5,754
citations

109264

35
h-index

79644

73
g-index

110
all docs

110
docs citations

110
times ranked

7719
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Determination of hepatic clearance by derivations of the indocyanine green retention test in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 692-699. | 1.4 | 0 |
| 2 | Inflammatory Bowel Diseases Affect the Phenotype and Disease Course of Coexisting Immune-Mediated Inflammatory Diseases: A Systematic Review With Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , 2022, , . | 0.9 | 5 |
| 3 | Gastric Emptying Is Not Delayed and Does Not Correlate With Attenuated Postprandial Blood Flow Increase in Medicated Patients With Early Parkinson's Disease. <i>Frontiers in Neurology</i> , 2022, 13, 828069. | 1.1 | 2 |
| 4 | Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease " a systematic review with meta-analysis. <i>Digestive and Liver Disease</i> , 2022, 54, 1168-1178. | 0.4 | 17 |
| 5 | Influence of NAFLD and bariatric surgery on hepatic and adipose tissue mitochondrial biogenesis and respiration. <i>Nature Communications</i> , 2022, 13, . | 5.8 | 14 |
| 6 | Outcomes of COVID-19 among Patients with Chronic Liver Disease: A Danish Prospective, Population-Based Cohort Study. <i>GastroHep</i> , 2022, 2022, 1-10. | 0.3 | 1 |
| 7 | Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. <i>Gut</i> , 2021, 70, gutjnl-2019-320170. | 6.1 | 47 |
| 8 | Systematic Review with Meta-analysis: The Impact of Co-occurring Immune-mediated Inflammatory Diseases on the Disease Course of Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 927-939. | 0.9 | 16 |
| 9 | Systematic review and meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease localization and behavior of Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110048. | 1.4 | 2 |
| 10 | Hepatic Steatosis Associated With Exposure to Elvitegravir and Raltegravir. <i>Clinical Infectious Diseases</i> , 2021, 73, e811-e814. | 2.9 | 10 |
| 11 | A Danish population-based case series of patients with liver cirrhosis and coronavirus disease 2019. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 453-457. | 0.6 | 3 |
| 12 | Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies " A Danish population-based cohort study. <i>Journal of Autoimmunity</i> , 2021, 118, 102613. | 3.0 | 41 |
| 13 | Fecal microbiota transplantation in hepatic encephalopathy: a systematic review. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 560-569. | 0.6 | 26 |
| 14 | Postprandial Increase in Mesenteric Blood Flow is Attenuated in Parkinson's Disease: A Dynamic PC-MRI Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 545-557. | 1.5 | 1 |
| 15 | Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn's disease " a real-world two-center cohort study. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e709-e718. | 0.8 | 11 |
| 16 | Using MR elastography to assess portal hypertension and response to beta-blockers in patients with cirrhosis. <i>Liver International</i> , 2021, 41, 2149-2158. | 1.9 | 15 |
| 17 | Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 1040-1048. | 0.6 | 12 |
| 18 | Progressive alcohol-related liver fibrosis is characterised by imbalanced collagen formation and degradation. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1070-1080. | 1.9 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Non-Alcoholic Fatty Liver Disease: A 12-Month Follow-Up Study with Paired Liver Biopsies. <i>Journal of Clinical Medicine</i> , 2021, 10, 3783. | 1.0 | 21 |
| 20 | Direct and Indirect Costs of Inflammatory Bowel Disease: Ten Years of Follow-up in a Danish Population-based Inception Cohort. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 53-63. | 0.6 | 39 |
| 21 | Poor Concordance Between Liver Stiffness and Noninvasive Fibrosis Scores in HIV Infection Without Viral Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 3049-3050. | 2.4 | 2 |
| 22 | Acetaminophen toxicity induces mitochondrial complex I inhibition in human liver tissue. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 86-91. | 1.2 | 8 |
| 23 | Dobutamine reverses the cardio-suppressive effects of terlipressin without improving renal function in cirrhosis and ascites: a randomized controlled trial. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G313-G321. | 1.6 | 10 |
| 24 | Increased Prevalence of Liver Fibrosis in People Living With Human Immunodeficiency Virus Without Viral Hepatitis Compared to Population Controls. <i>Journal of Infectious Diseases</i> , 2020, 224, 443-452. | 1.9 | 6 |
| 25 | Prevalence and Risk Factors of Moderate-to-Severe Hepatic Steatosis in Human Immunodeficiency Virus Infection: The Copenhagen Co-morbidity Liver Study. <i>Journal of Infectious Diseases</i> , 2020, 222, 1353-1362. | 1.9 | 17 |
| 26 | Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial. <i>BMJ Open</i> , 2020, 10, e035284. | 0.8 | 8 |
| 27 | Pathophysiological-based treatments of complications of cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 383-394. | 0.6 | 6 |
| 28 | Cardiodynamic state is associated with systemic inflammation and fatal acute-to-chronic liver failure. <i>Liver International</i> , 2020, 40, 1457-1466. | 1.9 | 46 |
| 29 | Left atrial volume changes assessed by real time 3-dimensional echocardiography in relation to liver function and prognosis in patients with cirrhosis. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 2121-2127. | 0.7 | 10 |
| 30 | Incidence, Risk Factors and Evaluation of Osteoporosis in Patients With Inflammatory Bowel Disease: A Danish Population-Based Inception Cohort With 10 Years of Follow-Up. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 904-914. | 0.6 | 15 |
| 31 | Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2020, 26, 5362-5374. | 1.4 | 17 |
| 32 | Health-related quality of life in inflammatory bowel disease in a Danish population-based inception cohort. <i>United European Gastroenterology Journal</i> , 2019, 7, 942-954. | 1.6 | 17 |
| 33 | Cardiac dysfunction in cirrhosis: a 2-yr longitudinal follow-up study using advanced cardiac imaging. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, G253-G263. | 1.6 | 19 |
| 34 | Collagen type IV remodelling gender-specifically predicts mortality in decompensated cirrhosis. <i>Liver International</i> , 2019, 39, 885-893. | 1.9 | 26 |
| 35 | An update on cirrhotic cardiomyopathy. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 497-505. | 1.4 | 33 |
| 36 | Indocyanine green retention test in cirrhosis and portal hypertension: Accuracy and relation to severity of disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1093-1099. | 1.4 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | A 10-Year Follow-up Study of the Natural History of Perianal Crohn's Disease in a Danish Population-Based Inception Cohort. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1227-1236. | 0.9 | 44 |
| 38 | Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis. <i>Hepatology Communications</i> , 2018, 2, 211-222. | 2.0 | 45 |
| 39 | Pronounced Coronary Arteriosclerosis in Cirrhosis: Influence on Cardiac Function and Survival?. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1355-1362. | 1.1 | 8 |
| 40 | Total bile acid levels are associated with left atrial volume and cardiac output in patients with cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 392-397. | 0.8 | 13 |
| 41 | Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 307-314. | 1.4 | 51 |
| 42 | Transjugular intrahepatic portosystemic shunt: impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, G275-G286. | 1.6 | 44 |
| 43 | The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. <i>Liver International</i> , 2018, 38, 570-580. | 1.9 | 136 |
| 44 | Low ascitic fluid total protein levels is not associated to the development of spontaneous bacterial peritonitis in a cohort of 274 patients with cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 200-205. | 0.6 | 5 |
| 45 | Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. <i>The Cochrane Library</i> , 2018, 2018, CD011510. | 1.5 | 29 |
| 46 | No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial. <i>PLoS ONE</i> , 2018, 13, e0203200. | 1.1 | 6 |
| 47 | Myocardial extracellular volume quantified by magnetic resonance is increased in cirrhosis and related to poor outcome. <i>Liver International</i> , 2018, 38, 1614-1623. | 1.9 | 30 |
| 48 | Gamma-carrinate plasma clearance versus urinary plasma clearance of ⁵¹ Cr-EDTA in patients with cirrhosis with and without fluid retention. <i>Clinical Physiology and Functional Imaging</i> , 2017, 37, 588-595. | 0.5 | 2 |
| 49 | Bile acids and cardiovascular function in cirrhosis. <i>Liver International</i> , 2017, 37, 1420-1430. | 1.9 | 44 |
| 50 | Proximal Disease Extension in Patients With Limited Ulcerative Colitis: A Danish Population-based Inception Cohort. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1200-1204. | 0.6 | 34 |
| 51 | The royal free hospital cirrhosis glomerular filtration rate: Validation in a danish cohort. <i>Hepatology</i> , 2017, 66, 1360-1361. | 3.6 | 3 |
| 52 | Cardiovascular Effects of a Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis. <i>Current Hepatology Reports</i> , 2017, 16, 250-257. | 0.4 | 0 |
| 53 | NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8+ T cell migration. <i>Experimental and Molecular Pathology</i> , 2017, 103, 56-70. | 0.9 | 16 |
| 54 | Effects of transjugular intrahepatic portosystemic shunt (TIPS) on blood volume distribution in patients with cirrhosis. <i>Digestive and Liver Disease</i> , 2017, 49, 1353-1359. | 0.4 | 24 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. <i>Hepatology</i> , 2017, 65, 592-603. | 3.6 | 60 |
| 56 | Aquaporin-2 excretion in hospitalized patients with cirrhosis: Relation to development of renal insufficiency and mortality. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1087-1093. | 1.4 | 3 |
| 57 | Neutrophil gelatinase-associated lipocalin and cystatin C in cirrhosis and portal hypertension: Relations to organ extraction and dysfunction. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 473-481. | 1.4 | 5 |
| 58 | Red blood cell sodium transport in patients with cirrhosis. <i>Clinical Physiology and Functional Imaging</i> , 2016, 36, 359-367. | 0.5 | 0 |
| 59 | Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 310, E505-E514. | 1.8 | 56 |
| 60 | Presence of alcoholic steatohepatitis, but no selective histological feature, indicates an increased risk of cirrhosis and premature death. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1367-1374. | 0.6 | 5 |
| 61 | The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1407-1415. | 0.6 | 159 |
| 62 | Hepatorenal syndrome in cirrhosis: diagnostic, pathophysiological, and therapeutic aspects. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1153-1161. | 1.4 | 15 |
| 63 | Plasma ADAMTS-13 protein is not associated with portal hypertension or hemodynamic changes in patients with cirrhosis. <i>Digestive and Liver Disease</i> , 2016, 48, 404-408. | 0.4 | 6 |
| 64 | Assessment of response to beta-blockers by expression of β_2 Arr2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients. <i>Journal of Hepatology</i> , 2016, 64, 1265-1273. | 1.8 | 27 |
| 65 | Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2016, 64, 574-582. | 1.8 | 196 |
| 66 | Pro-C5, a marker of true type V collagen formation and fibrillation, correlates with portal hypertension in patients with alcoholic cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 584-592. | 0.6 | 43 |
| 67 | Cirrhotic Multiorgan Syndrome. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3209-3225. | 1.1 | 35 |
| 68 | Cardiovascular complications of NAFLD—they do matter. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 434-436. | 8.2 | 3 |
| 69 | Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2015, 149, 389-397.e10. | 0.6 | 2,200 |
| 70 | Management of cirrhotic ascites. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 124-137. | 1.1 | 55 |
| 71 | PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension. <i>PLoS ONE</i> , 2014, 9, e108544. | 1.1 | 29 |
| 72 | Hospitalisation, surgical and medical recurrence rates in inflammatory bowel disease 2003–2011—A Danish population-based cohort study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1675-1683. | 0.6 | 54 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Mortality, Cancer, and Comorbidities Associated With Chronic Pancreatitis: A Danish Nationwide Matched-Cohort Study. <i>Gastroenterology</i> , 2014, 146, 989-994.e1. | 0.6 | 177 |
| 74 | Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes. <i>Liver International</i> , 2014, 34, 1153-1163. | 1.9 | 40 |
| 75 | Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: A randomised study. <i>Digestive and Liver Disease</i> , 2014, 46, 251-256. | 0.4 | 19 |
| 76 | Reply. <i>Gastroenterology</i> , 2014, 147, 542. | 0.6 | 11 |
| 77 | Disease Course and Surgery Rates in Inflammatory Bowel Disease: A Population-Based, 7-Year Follow-Up Study in the Era of Immunomodulating Therapy. <i>American Journal of Gastroenterology</i> , 2014, 109, 705-714. | 0.2 | 150 |
| 78 | Effect of recombinant Factor VIIa on outcome of acute variceal bleeding: An individual patient based meta-analysis of two controlled trials. <i>Journal of Hepatology</i> , 2014, 61, 252-259. | 1.8 | 43 |
| 79 | The Risk of Fractures Among Patients With Cirrhosis or Chronic Pancreatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 320-326. | 2.4 | 61 |
| 80 | Cardiac Function in Patients with Early Cirrhosis during Maximal Beta-Adrenergic Drive: A Dobutamine Stress Study. <i>PLoS ONE</i> , 2014, 9, e109179. | 1.1 | 15 |
| 81 | Extrahepatic complications to cirrhosis and portal hypertension: Haemodynamic and homeostatic aspects. <i>World Journal of Gastroenterology</i> , 2014, 20, 15499. | 1.4 | 62 |
| 82 | Lactate metabolism in chronic liver disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2013, 73, 293-299. | 0.6 | 110 |
| 83 | Carvedilol or propranolol in portal hypertension? A randomized comparison. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 467-474. | 0.6 | 47 |
| 84 | Treatment of ascites and spontaneous bacterial peritonitis - part I. <i>Danish Medical Journal</i> , 2012, 59, C4371. | 0.5 | 4 |
| 85 | Pitfalls in the assessment of intrapulmonary shunt using lung perfusion scintigraphy in patients with cirrhosis: authors' reply. <i>Liver International</i> , 2011, 31, 139-140. | 1.9 | 0 |
| 86 | Long-Term, Clinical Follow-Up in Fatty Liver Patients. <i>Digestive Diseases</i> , 2010, 28, 709-714. | 0.8 | 5 |
| 87 | Pharmacological effects are model specific in animal models of portal hypertension. <i>Hepatology International</i> , 2008, 2, 397-398. | 1.9 | 2 |
| 88 | Diurnal variation and dispersion in QT interval in cirrhosis: Relation to haemodynamic changes. <i>Journal of Hepatology</i> , 2007, 47, 373-380. | 1.8 | 45 |
| 89 | Determinants of the renin-angiotensin-aldosterone system in cirrhosis with special emphasis on the central blood volume. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 451-458. | 0.6 | 37 |
| 90 | Effects of tilting on central hemodynamics and homeostatic mechanisms in cirrhosis. <i>Hepatology</i> , 2004, 40, 811-819. | 3.6 | 28 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Acute non-selective β_2 -adrenergic blockade reduces prolonged frequency-adjusted QT interval (QTc) in patients with cirrhosis. <i>Journal of Hepatology</i> , 2004, 40, 239-246. | 1.8 | 116 |
| 92 | Central and noncentral blood volumes in cirrhosis: relationship to anthropometrics and gender. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 284, G970-G979. | 1.6 | 59 |
| 93 | Arterial compliance in patients with cirrhosis: stroke volume-pulse pressure ratio as simplified index. <i>American Journal of Physiology - Renal Physiology</i> , 2001, 280, G584-G594. | 1.6 | 55 |
| 94 | The insulin-like growth factor binding protein 3 ternary complex is reduced in cirrhosis. <i>Liver</i> , 2001, 21, 350-356. | 0.1 | 9 |
| 95 | Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: A randomized, double-blind, controlled trial. <i>Hepatology</i> , 2001, 34, 471-477. | 3.6 | 26 |
| 96 | Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. <i>Liver</i> , 2000, 20, 51-59. | 0.1 | 120 |
| 97 | Effects on Plasma Angiotensin-Converting Enzyme Activity and Circulating Renin of Lisinopril and Enalapril Alone and in Combination with Propranolol in Healthy Volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1999, 84, 110-114. | 0.0 | 4 |
| 98 | Increased circulating leptin in alcoholic cirrhosis: Relation to release and disposal. <i>Hepatology</i> , 1999, 29, 1818-1824. | 3.6 | 92 |
| 99 | Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. <i>Gastroenterology</i> , 1995, 109, 1917-1925. | 0.6 | 130 |
| 100 | Assessment of central blood volume in cirrhosis by radionuclide angiography: What does it really mean?. <i>Hepatology</i> , 1994, 20, 1652-1656. | 3.6 | 9 |
| 101 | Estimated central blood volume in cirrhosis: Relationship to sympathetic nervous activity, β_2 -adrenergic blockade and atrial natriuretic factor. <i>Hepatology</i> , 1992, 16, 1163-1170. | 3.6 | 76 |
| 102 | Estimated central blood volume in cirrhosis: Relationship to sympathetic nervous activity, β_2 -adrenergic blockade and atrial natriuretic factor. <i>Hepatology</i> , 1992, 16, 1163-1170. | 3.6 | 3 |
| 103 | Effect of oral propranolol administration on azygos, renal and hepatic uptake and output of catecholamines in cirrhosis. <i>Hepatology</i> , 1991, 14, 237-243. | 3.6 | 28 |
| 104 | Serum levels of short-chain fatty acids in cirrhosis and hepatic coma. <i>Hepatology</i> , 1991, 14, 1040-1045. | 3.6 | 16 |
| 105 | Splanchnic and renal extraction of circulating type III procollagen aminoterminal propeptide in patients with normal liver function and in patients with alcoholic cirrhosis. <i>Hepatology</i> , 1990, 11, 957-963. | 3.6 | 25 |
| 106 | Bacteraemia after injection sclerotherapy of oesophageal varices. <i>Liver</i> , 1988, 8, 167-171. | 0.1 | 11 |
| 107 | Hepatic venous oxygen content in alcoholic cirrhosis and non-cirrhotic alcoholic liver disease. <i>Liver</i> , 1987, 7, 176-181. | 0.1 | 16 |
| 108 | Circulating atrial natriuretic peptide (ANP) and central blood volume (CBV) in cirrhosis. <i>Liver</i> , 1986, 6, 361-368. | 0.1 | 51 |